Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Accumulated Expenses: 2017-2022

Historic Other Accumulated Expenses for Denali Therapeutics (DNLI) over the last 2 years, with Dec 2022 value amounting to $4.4 million.

  • Denali Therapeutics' Other Accumulated Expenses fell 91.75% to $4.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.4 million, marking a year-over-year decrease of 91.75%. This contributed to the annual value of $4.4 million for FY2022, which is 91.75% down from last year.
  • According to the latest figures from Q4 2022, Denali Therapeutics' Other Accumulated Expenses is $4.4 million, which was down 91.75% from $53.2 million recorded in Q4 2021.
  • Over the past 5 years, Denali Therapeutics' Other Accumulated Expenses peaked at $53.2 million during Q4 2021, and registered a low of $47,000 during Q2 2018.
  • For the 3-year period, Denali Therapeutics' Other Accumulated Expenses averaged around $34.9 million, with its median value being $47.1 million (2020).
  • As far as peak fluctuations go, Denali Therapeutics' Other Accumulated Expenses skyrocketed by 30,801.59% in 2018, and later plummeted by 91.75% in 2022.
  • Denali Therapeutics' Other Accumulated Expenses (Quarterly) stood at $19.5 million in 2018, then increased by 23.36% to $24.0 million in 2019, then surged by 96.31% to $47.1 million in 2020, then grew by 12.77% to $53.2 million in 2021, then tumbled by 91.75% to $4.4 million in 2022.
  • Its Other Accumulated Expenses stands at $4.4 million for Q4 2022, versus $53.2 million for Q4 2021 and $47.1 million for Q4 2020.